Niagen Bioscience launches pharmaceutical program for aging and genetic diseases

Niagen Bioscience formally launched the first drug candidate of NAD Pharmaceuticals, its wholly owned subsidiary focused on developing therapies for accelerated aging and rare genetic diseases. The program will primarily focus on how NAD+, a coenzyme central to energy metabolism, DNA repair, mitochondrial function and cellular stress responses, modulates in rare diseases for which DNA misrepair and mitochondrial dysfunction are foundational underlying causes. This represents a strategic expansion of Niagen Bioscience's NAD+ platform from cellular-health innovation into regulated drug development. A-T is a rare genetic disease characterized by progressive loss of motor coordination, impaired immune function, increased susceptibility to infections, pulmonary complications, and a substantially elevated risk of cancer. There are currently no FDA-approved therapies for A-T, and treatment is largely limited to supportive care. NB4168 is not commercially available as a supplement or approved drug and has coverage by Niagen Bioscience's patent portfolio.